Successful multimodal management of rhabdomyosarcoma and dento-facial sequelae of treatment  by Askew, C. et al.
Oral Oncology EXTRA (2006) 42, 52–55http://intl.elsevierhealth.com/journal/ooexCASE REPORTSuccessful multimodal management
of rhabdomyosarcoma and dento-facial
sequelae of treatmentC. Askew *, P.S. Fleming, T.R. FloodOdstock Centre for Burns, Plastic and Maxillofacial Surgery, Salisbury District Hospital,
Odstock Road, Salisbury SP2 8BJ, United KingdomReceived 31 August 2005; accepted 31 August 2005Summary Rhabdomyosarcoma (RMS) is an aggressive malignant neoplasm associ-
ated with high morbidity. We describe a case of embryonal rhabdomyosarcoma trea-
ted successfully with combination radiotherapy and chemotherapy.c 2005 Elsevier Ltd. All rights reserved.
KEYWORDS
Embryonal;
Rhabdomyosarcoma;
Chemotherapy;
Radiotherapy;
Mucositis;
Xerostomia;
Root development1
d
CIntroduction
Rhabdomyosarcoma (RMS) is a malignant neoplasm
composed of neoplastic mesenchymal cells with
varying degrees of striated muscle differentiation.
It is the most common sarcoma in children,
accounting for 4–8% of all cases of malignant dis-
ease under 15 years of age.1 There is a pronounced
predilection of RMS to children, most commonly
affecting males.2741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
oi:10.1016/j.ooe.2005.08.010
* Corresponding author. Address: 9 Beach Park, Portmarnock,
o. Dublin, Ireland. Tel.: +353872199390.
E-mail address: carolineaskew1@hotmail.com (C. Askew).RMS commonly presents as persistent swelling
which is often painful, though not exclusively so.
Other reported symptoms of perioral RMS include
dysphagia, trismus, and paraesthesia.3 Anatomi-
cally RMS is divided into two subtypes: paramenin-
geal (including RMS of the nasopharynx, paranasal
sinuses, nose, infratemporal fossa, and pterygopal-
atine fossa) and nonparameningeal (including
disease of the oral cavity, oropharynx, parotid
gland, larynx, and parotid gland). Sites of predilec-
tion in the head and neck include the tongue and
palate.
Head and neck RMS has a distinct prognosis and
biologic behaviour. RMS has four distinct histopa-
thological subtypes: embryonal, alveolar, pleomor-
phic and undifferentiated. The embryonal subtypeved.
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young patients and frequently arises in the perioral
region.4
Formerly, surgical excision was the only thera-
peutic modality available for RMS. However, com-
bination therapy has replaced surgery as the
standard of care with encouraging results.
This case report highlights the significant
improvement in outcome offered by multimodal
management of rhabdomyosarcoma. The turbulent
nature of the active treatment phase aswell as the
local sequelae of the combination therapy are also
described.Figure 1 Pre-treatment CT scan.
Figure 2 Post-treatment panoramic radiograph.Case report
An 8-year-old female was referred to the Oral and
Maxillofacial Surgery Department by her medical
practitioner with a three day history of a right-
sided buccal swelling. The swelling had been unre-
sponsive to empiric oral antibiotic treatment.
Initially, a dental origin was considered with the
upper right first molar being tender to percussion,
but responding positively to vitality testing. Oral
antibiotics were continued for four further days.
However, the swelling failed to resolve.
The patient was admitted for an examination
under anaesthetic and incisional biopsy. On closer
digital examination the mass appeared to extend
into the right parapharyngeal space. The histopa-
thology report described a tumour of small spindle
cells in a loose myxoid ground substance. The
appearance was consistent with embryonal rhabdo-
myosarcoma. Immunocytochemistry results con-
firmed this.
Further investigations were performed to deci-
pher the precise location, spread and prognosis of
the condition. A CT scan confirmed an extensive
soft tissue tumour, measuring 3.5 cm · 3.5 cm in
the right parapharyngeal space, buccal space and
infra-temporal fossa (Fig. 1). Enlarged lymph nodes
(>1 cm) were also noted in the parotid gland and
superior mediastinum. A sub-pleural nodule was
apparent on the chest CT scan.
The patient was referred to a paediatric oncolo-
gist. Treatment was commenced in accordance
with an International Society of Paediatric Oncol-
ogy (SIOP) protocol for management of high risk
sarcomas. The patient was allocated to a 6 drug
arm chemotherapy treatment strategy. Agents
used included carboplatin, epirubicin, and vincris-
tine (CEV) and ifosfamide, vincristine, and etopo-
side (IVE). Chemotherapy was administered over a
27 week period and adjuvant high-dose radiother-
apy added at week 9.During the active phase of treatment the patient
developed a series of problems including painful
radiation-induced oropharyngeal mucositis. This
culminated in an inability to eat necessitating gas-
trostomy tube insertion. The patient was also
admitted on two occasions with febrile neutrope-
nia and developed right upper lobe pneumonia.
Within 2 months of completion of active treat-
ment the patient had recovered significantly. She
was improved systemically and began to regain
weight steadily. Four years after completion of
the active phase of treatment the patient has only
minor residual problems including a degree of xero-
stomia and a generalized arrest of root develop-
ment, particularly affecting the second premolars
and second permanent molars (Fig. 2). The patient
was also reassessed by a consultant maxillofacial
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mandibular ramus. Intervention was felt unneces-
sary. Generally the patient is thriving with growth
within the normal range for her age. There has
been no evidence of local or regional tumour
recurrence.Discussion
RMS is a highly aggressive neoplasm capable of
rapid local invasion and bony infiltration. The
non-specific and somewhat unremarkable initial
symptoms, including painless swelling, trismus
and paraesthesia, often make early diagnosis diffi-
cult.5 The time interval between onset of symp-
toms and correct diagnosis of head and neck RMS
is estimated at 1–17 months.6 Our patient sought
treatment early ensuring a definitive diagnosis
was made with in two weeks of onset of the swell-
ing. The importance of biopsy of suspected inflam-
matory swellings if pus is not obtained after
drainage is obvious.
Initially surgery was the sole therapeutic modal-
ity available for RMS.7 Surgery tended to be radical
and associated with significant morbidity if com-
plete excision was to be achieved. Recurrence
rates were high due to propensity of RMS to uncon-
trolled local invasion and metastatic spread. The
condition carried an attendant poor prognosis.8
The potential role of radiotherapy in management
of recurrent RMS emerged.9 Thereafter, the bene-
fits of a multimodal approach involving combina-
tions of surgery, chemotherapy and radiotherapy
became clear.10 A six drug combination in accor-
dance with an international protocol for RMS was
used, with adjunctive radiotherapy.11 The possibil-
ity of surgical resection of the mass or part thereof
was considered. In view of the size of the primary
lesion, rapid tumour proliferation and metastatic
spread the combination of radiotherapy and che-
motherapy alone was deemed most prudent.
High-dose radiation and chemotherapy can inde-
pendently provoke a plethora of oral complications
including mucositis, xerostomia, loss of taste,
opportunistic infection, trismus, erythema, and
impaired dental and osseous development.12 Con-
comitant use of both modalities exacerbates these
difficulties. Radiotherapy in isolation may result in
rampant dental caries, and can induce osteoradio-
necrosis as a consequence of hypovascular, hypo-
cellular and hypoxic changes.13 Our patient
developed severe, painful oropharyngeal mucositis
causing odynophagia, which ultimately necessi-
tated gastrostomy placement. She also continuesto complain of some xerostomia. However, her
dental health has been maintained due to regular
dental review, dietary changes, fluoride mouthrin-
sing and scrupulous oral hygiene. Generally, the
susceptibility to post-treatment complications is
reduced by prompt implementation of well-defined
preventive regimes.14
The generalized arrest of root development is
likely to be related to both treatment modalities,
though primarily due to the high-dose radiother-
apy.15 Foreshortening and blunting of roots, incom-
plete calcification, premature apex closure, and
tooth agenesis have also been attributed to radio-
therapy and chemotherapy.16 Immature teeth tend
to be more susceptible to developmental distur-
bance than mature teeth.17 This pattern is appar-
ent in our patient. The absence of the mandibular
third molars may also be related to the high-dose
radiotherapy.References
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